1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
InnoCare Pharma Ltd. Class A

InnoCare Pharma Ltd. Class A

1.60
USD
-0.25
(-13.51%)
-0.03EPS
Oct 26Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
0.3
0.17
0.17
0.24
1.35
0.32
Basic EPS, GAAP
-0.11
-0.18
-0.68
-0.16
-0.02
-0.24
-0.15
-0.1
0.36
-0.19
Free Cash Flow per Basic Share
-0.02
-0.01
-0.05
-0.17
- -
-0.25
-0.22
-0.1
0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.12
-0.29
-0.96
0.96
1.49
1.72
1.61
1.52
1.75
1.56
Tangible Book Value per Share
-0.14
-0.33
-0.99
0.92
1.47
1.71
1.61
1.51
1.74
1.55
Basic Weighted Avg Shares
3,142
3,142
3,142
2,429
3,430
3,715
4,237
4,245
1,762
2,439
Sales/Revenue/Turnover
- -
2
1
1
1,043
625
739
1,009
2,375
781
Operating Margin (%)
-65,706.86
-9,192.76
-20,098.56
-36,257.11
-15.94
-116.91
-88.35
-52.09
20.88
-82.26
Depreciation Expense
4
5
9
11
34
68
93
106
118
- -
Net Income, GAAP
-342
-550
-2,141
-391
-65
-887
-631
-441
642
-471
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
1.76
- -
Profit Margin (%)
-335,033.33
-34,010.51
-171,723.18
-28,694.65
-6.19
-141.76
-85.47
-43.65
27.05
-60.31
Working Capital
-52
1,991
2,343
3,988
6,088
7,224
6,671
6,759
6,664
5,959
LT Debt
57
965
1,121
1,167
1,248
35
70
1,046
1,021
74
Total Equity
-392
-838
-2,948
3,161
5,659
7,644
7,181
6,746
7,749
6,938
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
5.67
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
8.14
- -
Return on Common Equity (%)
- -
- -
- -
- -
-1.48
-13.43
-8.56
-6.35
8.89
-6.55

Capital Structure

CNY

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
1,279
- -
1,314
LT Borrowings
26
33
34
LT Finance Leases
44
36
40
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,427
4,425
4,425
Market Capitalization
- -
- -
- -

Working Capital

CNY

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
8,765
8,621
8,071
Cash, Cash Equivalents & STI
8,225
8,202
7,547
Accounts Receivable, Net
277
233
282
Inventories
119
118
118
Total Current Liabilities
2,094
2,055
2,112
Payables & Accruals
- -
- -
- -
ST Debt
1,279
- -
1,314
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
23.38%
14.87%
Free Cash Flow
- -
4,435.96%
-103.1%
Net Income, GAAP
- -
177.06%
-245.81%
Sales/Revenue/Turnover
- -
15,303.74%
135.27%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
189
188
160
201
739
2024
166
254
- -
- -
1,009
2025
- -
- -
- -
- -
2,375

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
-0.23
-0.06
-0.06
-0.15
2024
-0.03
-0.07
- -
- -
-0.1
2025
- -
- -
- -
- -
0.36

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jisong Cui
Full Time Employees
1,259
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building 8 Beijing BE China 102206
IPO Date
Mar 23, 2020
Website
innocarepharma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
InnoCare Pharma Limited (9969.HK) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class or best-in-class medicines for cancer and autoimmune diseases. The company offers a pipeline of innovative drug candidates targeting difficult-to-treat diseases, including small molecule inhibitors such as TYK2 inhibitor ICP-332 for autoimmune disorders, BTK inhibitor ICP-490 for oncology and immunology, PI3Kδ inhibitor ICP-1401 for B-cell malignancies, and oral PD-L1 inhibitors ICP-209 and ICP-222 for solid tumors; it also advances antibody-drug conjugates like ICP-101 for solid tumors and preclinical assets in PROTACs and antibody therapeutics. InnoCare operates primarily in Greater China with global clinical trial footprints in North America, Europe, and Asia-Pacific, targeting patients with oncology and autoimmune conditions through partnerships with leading research institutions and pharmaceutical firms. Founded in 2016 and headquartered in Beijing, China, the company has no listed parent but maintains subsidiaries in the United States and Hong Kong to support international development. Recent major developments include the positive topline results from the Phase 2 RA trial of ICP-332 announced in late 2024, advancing its potential as a best-in-class TYK2 inhibitor; strategic expansions into earlier pipeline assets with ongoing Phase 1/2 trials for ICP-490 and ICP-1401 as of mid-2025; and strengthened collaborations with global CROs for accelerated global filings, alongside successful Series D+ funding rounds exceeding RMB 2 billion to fuel late-stage advancements.

Company News

Company News APIChatGPT

  • globenewswire.com

    InnoCare Announces Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Sjögren's Syndrome in China

  • globenewswire.com

    InnoCare Announces Approval of Clinical Trial of Novel CDH7 targeted ADC ICP-B208 in China

  • globenewswire.com

    InnoCare Announces First Patient Dosed in Phase III Trial of Orelabrutinib for SLE

  • globenewswire.com

    InnoCare Announces First Patient Dosed in the Phase II/III Clinical Trial of Novel TYK2 Inhibitor Soficitinib for Chronic Spontaneous Urticaria in China

  • globenewswire.com

    InnoCare Announces IND Approval to Initiate Clinical Trial of VAV1 Degrader ICP-538 in China

  • globenewswire.com

    Latest Data of InnoCare’s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)